Neurent Medical provides the NEUROMARK® System, a minimally invasive, office‑based procedure that uses low‑energy radiofrequency to create precise micro‑lesions in overactive posterior nasal nerves, the root cause of chronic rhinitis. The treatment delivers rapid symptom relief with no downtime and has demonstrated durable efficacy in clinical studies, offering ENT physicians a safe, reimbursable alternative to daily medication or invasive surgery.
Funding
Funding not disclosed
CCFounders
Product
Problem
Chronic rhinitis affects a large portion of the adult population, causing persistent nasal congestion, sneezing, runny nose, and post‑nasal drip that impair sleep, cognition, and overall quality of life. Current management relies on daily medications or invasive surgery, both of which have compliance issues, side effects, or long recovery times.
Solution
Neurent Medical offers the NEUROMARK® System, a minimally invasive, office‑based procedure that uses controlled low‑energy radiofrequency to create precise micro‑lesions in the overactive posterior nasal nerves (PNN), the primary source of chronic rhinitis symptoms. The low‑power energy delivery is brief, typically lasting only a few minutes, and requires no downtime, allowing patients to resume normal activities immediately. Clinical studies (e.g., CLARITY and PARAGON) have demonstrated statistically significant and durable symptom improvement, with an 80% responder rate at 12 months and sustained benefits over two years. The procedure is covered by Medicare/Medicaid and many commercial insurers, facilitating patient access. By targeting the nerve source rather than managing downstream symptoms, NEUROMARK provides long‑lasting relief without the need for ongoing medication or extensive surgery.
Target Audience
Primary customers are otolaryngologists (ENT physicians) seeking an effective, in‑office treatment for patients with allergic or non‑allergic chronic rhinitis who have inadequate response to medical therapy.
Features
- Proprietary ENTelligent™ technology that delivers impedance‑controlled low‑energy radiofrequency to posterior nasal nerves
- Precise micro‑lesion creation with real‑time energy monitoring for consistent treatment depth and safety
- Office‑based workflow: procedure time of only a few minutes and typically no postoperative downtime
- Clinically validated efficacy: 80% of patients achieve ≥30% reduction in total nasal symptom score at 12 months
- Durable outcomes demonstrated in 2‑year follow‑up studies, showing sustained symptom relief and quality‑of‑life improvements
- Reimbursement support through MyMark™ services, including prior‑authorization assistance and billing guidance
- Compatibility with standard ENT examination settings and no requirement for specialized surgical facilities